- Home
- SUGP vs APRE Comparison
SUGP vs APRE Comparison
Compare SUGP & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- APRE
- Stock Information
- Founded
- SUGP 1998
- APRE 2006
- Country
- SUGP Hong Kong
- APRE United States
- Employees
- SUGP N/A
- APRE N/A
- Industry
- SUGP
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUGP
- APRE Health Care
- Exchange
- SUGP NYSE
- APRE Nasdaq
- Market Cap
- SUGP 8.9M
- APRE 9.7M
- IPO Year
- SUGP 2024
- APRE 2019
- Fundamental
- Price
- SUGP $0.80
- APRE $1.75
- Analyst Decision
- SUGP
- APRE Strong Buy
- Analyst Count
- SUGP 0
- APRE 2
- Target Price
- SUGP N/A
- APRE $15.50
- AVG Volume (30 Days)
- SUGP 30.6K
- APRE 35.7K
- Earning Date
- SUGP 07-21-2025
- APRE 05-14-2025
- Dividend Yield
- SUGP N/A
- APRE N/A
- EPS Growth
- SUGP 1.19
- APRE N/A
- EPS
- SUGP 0.11
- APRE N/A
- Revenue
- SUGP $23,446,259.00
- APRE $1,284,475.00
- Revenue This Year
- SUGP N/A
- APRE N/A
- Revenue Next Year
- SUGP N/A
- APRE N/A
- P/E Ratio
- SUGP $7.62
- APRE N/A
- Revenue Growth
- SUGP 11.29
- APRE 33.27
- 52 Week Low
- SUGP $0.52
- APRE $1.41
- 52 Week High
- SUGP $3.25
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- SUGP 49.03
- APRE 49.51
- Support Level
- SUGP $0.76
- APRE $1.60
- Resistance Level
- SUGP $0.86
- APRE $2.00
- Average True Range (ATR)
- SUGP 0.08
- APRE 0.16
- MACD
- SUGP -0.02
- APRE 0.02
- Stochastic Oscillator
- SUGP 14.71
- APRE 37.50
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.